Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. frebt

FrEBT

Improving diagnostics of respiratory diseases and boosting the COMAC MEDICAL Ltd. competitiveness and growth by validation of fractional EBT biomarker through new method of measurement and device

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 FrEBT project word cloud

Explore the words cloud of the FrEBT project. It provides you a very rough idea of what is the project "FrEBT" about.

innovative    financial    14    markets    economic    causing    assessing    risk    15    morbidity    healthcare    million    precise    inflammatory    380    diagnosis    outcome    bln    niche    specialists    solution    diagnostic    gps    commercial    pulmonary    patients    full    countries    worldwide    lung    organization    20    monitoring    pulmonology    temperature    device    disruptive    validate    bulgaria    5    saving    technological    prognostic    diseases    comac    managerial    ip    oncology    population    regions    feasibility    prove    filling    alternative    market    fractional    obstructive    workforce    exhaled    young    organizational    trials    vulnerable    faster    socio    specialisation    elderly    mortality    deaths    launch    cancer    innovation    lives    profitability    breath    118    painful    eu28    12    children    network    competitiveness    global    respiratory    annually    ltd    description    invasive    share    people    groups    doctors    total    stages    service    clinical    mln    asia    biomarker    sme    region    medical    10    phase1   

Project "FrEBT" data sheet

The following table provides information about the project.

Coordinator		 COMAC MEDICAL LTD 

Organization address
address: 131 ODRIN STR AP 22
city: SOFIA
postcode: 1303
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Bulgaria [BG]
 Project website http://comac-medical.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    COMAC MEDICAL LTD BG (SOFIA) coordinator 50˙000.00

Map

 Project objective

The innovation project objectives are to: 1/prove through a feasibility study the potential to validate the Fractional Exhaled Breath Temperature, via new viable and disruptive technological device, as a diagnostic, prognostic and monitoring biomarker for inflammatory and obstructive pulmonary diseases; 2/enhance the competitiveness and profitability of the full- service clinical research organization COMAC MEDICAL Ltd., operating via own network of partners in 14 countries from 3 European regions with population of over 118 mln. The commercial potential of the innovative solution is that it is a best alternative of the existing methods on market, saving great number of diagnosis‘ stages without any potential risk for the patients, being more precise, user friendly, non-invasive, less painful, faster, cost effective, covering vulnerable groups of children, young and elderly people, saving lives, increasing workforce capabilities. It is a response to the EU wide and global challenges related to the respiratory diseases causing high level of morbidity and mortality–at about 1 million deaths annually in the European Region; 2/3 of them in EU28, with total cost there of € 380 bln. The expected SME growth is 20%, leading to specialisation in Pulmonology and Oncology and filling a market niche. The SME will launch into new markets in Europe and Asia, increasing its market share in clinical trials - 12-15% in Bulgaria;10% in Europe and 2-5% worldwide. The outcome of the Phase1 project is a feasibility study, assessing the socio-economic, commercial, technical aspects of the innovation, based on 6 steps of activities on: the Description of the innovative solution;Market/Technical Feasibility;Financial/Economic Feasibility; Organizational/Managerial Feasibility;Risk assessment;IP Management. The targeted users are the patients through the healthcare systems and the doctors, specialists in respiratory diseases and lung cancer as well as the GPs.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "FREBT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "FREBT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

GACD (2019)

Global Alliance for Chronic Diseases Secretariat

Read More  

CLOSER (2019)

Childhood Leukemia: Overcoming distance between South America and Europe Regions

Read More  

ESCALON (2019)

European-Latin American network for the assessment of biomarkers to predict and diagnose hepatobiliary malignancies and characterization of risk factors for cancer development

Read More